Technology
Top Growth Stocks to Consider for July 21
“`html On July 21, 2023, three stocks have been identified as strong buys by Zacks Investment Research, each holding a Zacks Rank #1 (Strong ...
Shifting Expectations: Analyzing Alphabet and Tesla’s Performance in Mag 7 Earnings
Tesla and Alphabet are scheduled to report their Q2 earnings in 2026, with Tesla’s shares down approximately 15% year-to-date. Despite exceeding EPS expectations by ...
Top Dividend Stocks to Consider for July 20th
On July 20, investors may want to consider buying stocks from Grupo Cibest S.A. (CIB) and Versant Media Group, Inc. (VSNT). Grupo Cibest, a ...
BayFirst Sees 16% Monthly Gain: Is It Time to Invest?
BayFirst Financial Corp. (BAFN) has seen its shares rise by 15.9% over the past month, significantly outperforming the banking industry’s growth rate of 4.6%. ...
Comparing Delta and United Airlines Stocks: Which One Offers More Value Post-Q2 Earnings?
Delta Air Lines (DAL) and United Airlines (UAL) reported better-than-expected Q2 results, indicating strong demand for premium and international travel. Delta’s adjusted earnings per ...
Analyzing Honeywell Aerospace Stock Performance Following Spin-Off Launch
Honeywell Aerospace Inc. (HONA) launched as a standalone company with a significant backlog of approximately $18.4 billion, providing a robust foundation for future revenues ...
Evaluating the Fair Value of Honeywell Aerospace Stock Post-Spinoff
Honeywell Aerospace Inc. (HONA) debuted on the public market in June 2026 after separating from Honeywell International, with a focus on commercial aviation, defense, ...
Aerospace Demand and Aftermarket Changes Driving HONA Growth Trends
Honeywell Aerospace (HONA) has positioned itself to capitalize on several aerospace growth sectors, including commercial aviation, defense, and space. The company benefits from rising ...
QURE Stock Prospects Dependent on AMT-130 Developments, FDA Discussions, and Financial Stability
uniQure N.V. (QURE) is focused on its gene therapy AMT-130, aimed at treating Huntington’s disease, a condition with no existing disease-modifying treatments. Recent FDA ...
Emerging Trends in Gene Therapy as Focus Expands Beyond Hemgenix at uniQure
uniQure N.V. (QURE) is transitioning its business model beyond HEMGENIX-related economics, focusing on regulatory speed and expanding its gene therapy portfolio. The company’s Huntington’s ...
